Background: Alkaline phosphatase has 4 isozymes, tissue non-specific alkaline phosphatase (TNAP), placental alkaline phosphatase (PLAP), intestinal alkaline phosphatase and germ-cell alkaline phosphatase. Hypophosphatasia (HPP) is an inherited skeletal disease caused by mutations of the gene encoding TNAP. Although TNAP is expressed in various tissues, the primary HPP symptoms appear in bones and teeth. The clinical severity of HPP varies widely from the most severe (perinatal, infantile and childhood) to the mildest forms (adult, and odonto-hypophosphatasia). We reported that gene therapy using a single injection of lentiviral vector expressing bone-targeted TNAP (TNAP-D 10 ) is effective in preventing all the skeletal of HPP in TNAP knockout (Alpl −/− ) mice as the model of infantile HPP. Objective: In this study we focus on evaluating the efficacy of treatment with gene therapy on the bone and teeth using TNAP-D 10 and also we investigate the feasibility of gene therapy using bone-targeted PLAP (PLAP-D 10 ). Methods and Findings: We used
Introduction
The human alkaline phosphatase family is composed of 4 isozymes, tissue nonspecific alkaline phosphatase (TNAP), placental alkaline phosphatase (PLAP), intestinal alkaline phosphatase and germ-cell alkaline phosphatase. Hypophosphatasia (HPP) is an inherited skeletal disease caused by mutations in the alkaline phosphatasegene (ALPL) encoding TNAP. Mutations in ALPL result in deficient activity of TNAP leading to skeletal and dental disease often causing death in the first year of life. Indeed, although TNAP is expressed in a variety of tissues, the HPP symptoms appear first in bones and teeth [1] . The main physiological substrate of TNAP responsible for the skeletal phenotype is the mineralization inhibitor inorganic pyrophosphate (PPi). The hypomineralization is caused by local accumulation of PPi inhibiting hydroxyapatite crystal growth [2] . The clinical severity of HPP varies widely. Listed from the most severe to the mildest forms HPP is classified as: perinatal, infantile, childhood, adult, and odonto-hypophosphatasia. The characteristic dental symptoms are the premature primary teeth defluxion, alveolar bone and enlarged dentalpulp chamber and teeth substances defects [3] .
HPP prevalence was reported in 1957 to be around 1:100,000 live births for the severe forms [4] . Recently, estimates of 1:300,000 have been reported for Europe [1] . Although the prevalence has not been established in Japan, it has been reported that c.1559delT in ALPL is the most frequent mutation, characteristic mutation of Japanese, and the heterozygote carrier is 1 in 480 Japanese [5] .
There is no established medical treatment of HPP.
In 2008, reports indicated that enzyme replacement therapy (ERT) using daily injections of bone-targeted TNAP (TNAP-D 10 ) is effective in preventing all the skeletal and dental manifestations of HPP in TNAP knockout (Alpl −/− ) mice [6] [7] [8] . Recently ERT has been approved for pediatric-onset HPP in Japan [9] .
However, the treatment entails daily subcutaneous injections and the treatment is expensive. Gene therapy offers potential advances on these issues. Several studies of gene therapy using viral vectors for murine HPP have been performed [14] . These treatments using the bone targeted TNAP-D 10 also proved effective for bone phenotype, especially the BMC transplantation improved teeth symptoms [15] .
In this study, we used a single injection of a viral vector and we focused on correction of the phenotype in the mandible, the alveolar bone and teeth in Alpl −/− mice using micro-CT and histological analysis. Furthermore we conducted bone histomorphometry to evaluate the therapeutic efficacy for long bones with single injection of lentiviral gene therapy. We also investigate the feasibility of gene therapy using bone-targeted placental alkaline phosphatase (PLAP-D 10 ), one of the isozymes of alkaline phosphatase.
Methods

Plasmid Construction
Polymerase chain reaction (PCR) was used as described previously [10] 
Lentiviral Vector Preparation
Lentivital vector was prepared by transfection in 293T cells, as described previously [10] .
The harvested viral containing medium was cleared by low speed centrifugation (500 g for 10 min at 4˚C), then filtrated through 0.45 µm pore size filter.
The filtrated medium was concentrated by ultracentrifuge with a 20% (w/v) 
Animal Procedures and Experiments
All animal experiments and animal care procedure were conducted with approval of the Animal Usage Committee of the Sanford Burnham Medical Research Institute, La Jolla, CA, USA. Alpl null mice were created as described previously [16] . 
Bone Histomorphometry
We followed Kawamoto's film method [18] . LGR μm/day = the length between alizarin red and calcein/the injected days from day 15 to day 20.
H&E Staining
The mandibles were fixed in 4% paraformaldehyde for 24 hours at 4˚C.
The undecalcified frozen sections from mice mandibles were prepared according to Kawamoto's film method [18] . The sections were cut into 5 μm thickness each samples.
Micro-CT Analysis
The micro-CT images were obtained using micro-CT (R_mCT2, Rigaku, Tokyo, Japan) and the images were reconstructed in three dimensions using 3-D construction analysis software (TRI/3D-BON, Ratoc System Engineering Co, Tokyo, Japan).
The conditions of micro-CT were 90 kV, 100 μA, magnification ×6.7 and measurement time 2 minutes. We measured the bone volumes (BV), bone mineral contents (BMC) and bone mineral density (BMD) of the mandibular bone and tissue mineral contents (TMC) and tissue mineral density (TMD) of the teeth, enamel and dentin as a region 2.0 mm from the tip of the incisors. The teeth regions analyzed every 30 μm/slice by the software.
Statistical Analysis
All statistical analysis was performed using SPSS (IBM Corp., Armonk, NY, USA). All data are expressed as the mean ± SD. ANOVA was used to determine differences between multiple groups, while differences between individual groups were determined by Tukey's test. p values < 0.05 was considered statistically significant.
Results
Comparison of the Long Bone Growth Rate with Bone Histmorphometry
Bone histomorphometry were performed at postnatal day 21. The first labels of alizarin rad were shown in red and the second labels of calcein were shown in green, the merged areas are shown in yellow (Figure 2 ).
WT mice had spacious calcified calcein stained area (Figure 2 
Histological Analysis of Mandibles with H&E Staining
The enamel and dentin defects were observed with incisors of untreated Alpl −/− mice on the sections of H&E staining at 21 days of age in agreement with earlier reports [8] , while incisors of WT mice showed uniformed and thickly enamel and dentin layers (Figure 4 (a), Figure 4(b) ).
The thick enamel and dentin were also present in the TNAP-D 10 
Micro-CT Analysis of Alveolar Bones and Teeth
To confirm the effect of lentiviral single injection therapy for not only long 
Discussion
Previously we showed that a single injection of either a lentiviral vector or an reported [15] . The above reports investigated long-term effects of the treatment for more than a month. These reports examined the long bones and teeth and indicated the correction of bone and dental phenotypes.
The current study investigated the effect of single lentiviral injection gene Several ERT studies using of mineral-targeted TNAP has been performed in HPP patients [9] . PLAP has not yet been used for ERT. However PLAP is physi- 
Conclusion
In conclusion these results indicate that bone-targeted TNAP treatment mediated by lentivirus can correct not only bone discloser but also dental symptoms in this mouse model of infantile HPP on day 21. This study also shows that PLAP-D 10 may possibly be used to correct some of the symptoms of HPP.
